CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 34.46×, higher than 95% of its Biotechnology peers (median 5.28×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.29BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.6750xvs all stocks
52-Week Change
-34.28%vs all stocks
Market Capitalization
2.29BUSDvs all stocks (USD)
Enterprise Value
1.72BUSDvs all stocks (USD)
Forward P/E
-10.34xvs Biotechnology peers
Price to Book (MRQ)
4.15xvs Biotechnology peers
Enterprise to EBITDA
-4.65xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-46.18%vs Biotechnology peers
Return on Equity (TTM)
-80.88%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 28, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-370.75MUSDvs all stocks (USD)
Net Income (TTM)
-349.58MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-138.79MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-203.46MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-170.60MUSDvs all stocks (USD)
Pre-tax Income
-154.65MUSDFY2025 · Dec 31, 2025Net Income
-154.65MUSDFY2025 · Dec 31, 2025EBIT
-170.60MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-170.54MUSDFY2025 · Dec 31, 2025Research & Development
132.01MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
38.59MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
15.95MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-154.65MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-145.31MUSDFY2025 · Dec 31, 2025Free Cash Flow
-145.33MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
172.92MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-154.65MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
59.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
19.32MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-9.88MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-166.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-15.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-814.74MUSDFY2025 · Dec 31, 2025Sale of Investments
425.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-389.75MUSDFY2025 · Dec 31, 2025Other Financing Charges
-391.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
577.97MUSDFY2025 · Dec 31, 2025Shares Outstanding
88.35MSharesUpdated Sep 28, 2026Float Shares
66.42MSharesUpdated Sep 28, 2026Shares Short
9.18MSharesUpdated Sep 28, 2026Short Ratio
8.04daysvs all stocks
Short % of Shares Outstanding
12.43%vs all stocks
% Held by Insiders
0.79%vs all stocks
% Held by Institutions
117.87%vs all stocks
Total Cash (MRQ)
661.41MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
7.48USDUpdated Sep 28, 2026Total Debt (MRQ)
97.62MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1772xvs Biotechnology peers
Current Ratio (MRQ)
34.46xvs Biotechnology peers
Book Value per Share (MRQ)
6.24USDUpdated Sep 28, 2026Total Assets
661.81MUSDvs all stocks (USD)
Total Current Assets
661.39MUSDFY2025 · Dec 31, 2025Total Liabilities
15.11MUSDFY2025 · Dec 31, 2025Total Non-current Assets
420.00KUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
0.00USDFY2025 · Dec 31, 2025Total Current Liabilities
15.11MUSDFY2025 · Dec 31, 2025Cash
1.03MUSDFY2025 · Dec 31, 2025Cash Equivalents
171.89MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
172.92MUSDFY2025 · Dec 31, 2025Other Short-term Investments
483.71MUSDFY2025 · Dec 31, 2025Accounts Payable
2.02MUSDFY2025 · Dec 31, 2025Common Stock (Book)
8.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-457.17MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
646.69MUSDvs all stocks (USD)
52-Week Low
22.30USDUpdated Sep 28, 202652-Week High
47.65USDUpdated Sep 28, 202652-Week Change
-34.28%vs all stocks
Beta
0.6750xvs all stocks
50-Day MA
27.14USDUpdated Sep 28, 2026200-Day MA
28.78USDUpdated Sep 28, 2026Avg 10-Day Volume
1.44MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.20MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-4.20USDUpdated Sep 28, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 34.46×, higher than 95% of its Biotechnology peers (median 5.28×)Significant
Current ratio: 34.46Industry median: 5.28Industry P95: 22.31Peers compared: 193
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Levered free cash flow is -$203.46M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -203,456,368Global P5: -202,685,365.334
Market cap is $2.29B, above the global median of $1.18BNotable
Market cap (USD): 2,286,202,046Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
ApicHope Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
GemPharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
ABL Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
UFP Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Pfizer Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pharvaris N.V.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shandong Buchang Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tonghua Dongbao Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Viridian Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Lingda Group Co., Ltd.
2 interpretationsLow-Leverage Liquidity ConfigurationLiquidity Ratios Elevated
Chengdu Galaxy Magnets Co., Ltd.
2 interpretationsLow-Leverage Liquidity ConfigurationLiquidity Ratios Elevated
Shenzhen Changhong Technology Co., Ltd.
2 interpretationsLow-Leverage Liquidity ConfigurationLiquidity Ratios Elevated